General information about company	
Scrip code*	533212
NSE Symbol*	NOTLISTED
MSEI Symbol*	BSE
ISIN*	INE265D01015
Name of company	GKB Ophthalmics Limited
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	30-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	14-05-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	OPHTHALMIC LENSES
Start date and time of board meeting	30-05-2025 17:15
End date and time of board meeting	30-05-2025 18:06
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	Showing !
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
atest Date on which RPT policy is updated	13-02-2025
indicate Company website link for updated RPT policy of the Company	www.gkb.net
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

	T Mancial	Results - Ind-AS		. 1	116415
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for c period ended (dd-mr 1-y		
	Date of start of reporting period	01-01-2025	01-	04-2024	
	Date of end of reporting period	31-03-2025	-1-	03-2025	
	Whether results are audited or unaudited	Audited		Audited	
	Nature of report standalone or consolidated	Standalone	Sta	ndalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated case zero shall be inserted in the said column.	Results, if the company has n	no figures for 3 months '6	months ended,	in such
1	Income				
	Revenue from operations	842.63		3274.94	
	Other income	1.1	1 1 1 1	197.22	
	Total income	843.73		3472.16	
2	Expenses				
(a)	Cost of materials consumed	481.28		1889.59	
(b)	Purchases of stock-in-trade	0.17		6.53	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	21.76		-49.82	
(d)	Employee benefit expense	272.72		1088.35	
(e)	Finance costs	59.73		188.67	
(f)	Depreciation, depletion and amortisation expense	66.44		264.31	
(g)	Other Expenses				
1	Other Expenses	185.43		688.16	
	Total other expenses	185.43		688.16	
	Total expenses	1087.53		4075.79	
3	Total profit before exceptional items and tax	-243.8		-603.63	
4	Exceptional items	0		0	
5	Total profit before tax	-243.8		-603.63	
6	Tax expense				
7	Current tax	0		0	1
8	Deferred tax	4.15	a granera TV -	7.16	
9	Total tax expenses	4.15		7.16	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0		0	
11	Net Profit Loss for the period from continuing operations	-247.95		-610.79	
12	Profit (loss) from discontinued operations before tax	0		0	
13	Tax expense of discontinued operations	0		0	
14	Net profit (loss) from discontinued operation after tax	0	str i vel	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	7 7	0	
16	Total profit (loss) for period	-247.95		-610.79	
17	Other comprehensive income net of taxes	-11.79		-20.36	
18	Total Comprehensive Income for the period	-259.74		-631.15	
19	Total profit or loss, attributable to	-4677.19		- State	
-	Profit or loss, attributable to owners of parent	- 1		F	
Н	Total profit or loss, attributable to non-controlling interests				
20					-
20	Total Comprehensive income for the period attributable to  Comprehensive income for the period attributable to owners of parent				
	Total comprehensive income for the period attributable to owners				

21	Details of equity share capital											
	Paid-up equity share capital	504.06	504.06									
	Face value of equity share capital	10	10	Ī								
22	Reserves excluding revaluation reserve		1263.36	Ī								
23	Earnings per share											
i	Earnings per equity share for continuing operations		· 4									
	Basic earnings (loss) per share from continuing operations	-4.92	-12.12	1								
	Diluted earnings (loss) per share from continuing operations	-4.92	-12.12	ĺ								
P   F   F	Earnings per equity share for discontinued operations											
	Basic earnings (loss) per share from discontinued operations	0	0									
	Diluted earnings (loss) per share from discontinued operations	0	0									
iii	Earnings per equity share (for continuing and discontinued op	erations)	21									
	Basic earnings (loss) per share from continuing and discontinued operations	-4.92	-12.12	1								
	Diluted earnings (loss) per share from continuing and discontinued operations	-4.92	-12.12	-								
4	Debt equity ratio			Textual Information(1)								
2.5	Debt service coverage ratio			Textual Information(2)								
6	Interest service coverage ratio			Textual Information( 3)								
27	Disclosure of notes on financial results	Textual Information(4)										

100.078	Text Block
Textual Information(4)	Text Block  3. The above standalone financial results for quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2025. The Standalone annual financial results have been subject to audit by the Statutory Auditors of the Company.  4. The utilisation / status of funds raised from preferential issue is as follows:-Particulars As at March 31, 2025 As at March 31, 2024 (Rs. In lakhs) (Rs. In lakhs) (Rs. In lakhs)  Towards funding growth plans - organic and inorganic 1170.00 1170.00 Towards scaling up of operations, long term capital requirements and other general corporate purpose 335.05 335.05 Total funds utilised (A) 1505.05 1505.05 Unutilised amount lying in Escrow account (B) - 7.22 Total funds raised (A + B) 1505.05 1512.27
	5. The Company operates in one primary segment only, i.e. Ophthalmics Lenses and therefore Ind AS 108 - Operating Segment is not applicable.  6. The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the statutory auditors.

_	Statement of Asset and Liabilities	
	Particulars	Year ended (dd-mm-yyyy)
_	Date of start of reporting period	01-04-2024
_	Date of end of reporting period	31-03-2025
_	Whether results are audited or unaudited	Audited
_	Nature of report standalone or consolidated	Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	1444
	Capital work-in-progress	378
	Investment property	
	Goodwill	
	Other intangible assets	
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	100
	Non-current investments	1189.
	Trade receivables, non-current	
	Loans, non-current	4. 1400 (2.176.176)
	Other non-current financial assets	4.10/201409-4.1014
	Total non-current financial assets	1194.
	Deferred tax assets (net)	28.
	Other non-current assets	235.
	Total non-current assets	3280.
	Current assets	
1	Inventories	608.
Ī	Current financial asset	1
Ī	Current investments	0.0
Ī	Trade receivables, current	
Ī	Cash and cash equivalents	748.
i	Bank balance other than cash and cash equivalents	88.
Ī	Loans, current	
1	Other current financial assets	104
Ī	Total current financial assets	184.0
i	Current tax assets (net)	1021.
١	Other current assets	27.0
1	Total current assets	37.1
1	Non-current assets classified as held for sale	1667.
١	Regulatory deferral account debit balances and related deferred tax Assets	
١	Total assets	
1		4948.5
1	Total current assets Non-current assets classified as held for sale	1667.77
1		
1	Regulatory deferral account debit balances and related deferred tax Assets	
J.	Total assets	4948.59
1	Equity and liabilities	

Equ	uity share capital	504.0
Ott	ner equity	1263.30
	Total equity attributable to owners of parent	1767.42
No	n controlling interest	
1	Total equity	1767.4 2
2 Lia	bilities	
No	n-current liabilities	
No	n-current financial liabilities	
Bor	rrowings, non-current	725.1
Tra	ade Payables, non-current	1 2 2 2 2 2 2
(A)	Total outstanding dues of micro enterprises and small enterprises	
(B)	Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
Oth	ner non-current financial liabilities	
	Total non-current financial liabilities	725.15
Pro	wisions, non-current	248
De	ferred tax liabilities (net)	ALLES A DOLLARS HORSE
De	ferred government grants, Non-current	I was all her become
Ott	her non-current liabilities	7. 1 (50%)
	Total non-current liabilities	973.55
Cu	rrent liabilities	P
Cu	rrent financial liabilities	le II =
Bo	rrowings, current	1083.4
Tr	ade Payables, current	21 11 11 12 11 11
	Total outstanding dues of micro enterprises and small enterprises	122.7
	Total outstanding dues of creditors other than micro enterprises and small enterprises	574.8
	Total Trade payable	697.57
Ott	her current financial liabilities	285.1
	Total current financial liabilities	2066.10
Ott	her current liabilities	53.2
	ovisions, current	88.2
	rrent tax liabilities (Net)	,a 1 1 1
	ferred government grants, Current	- in in in
1	Total current liabilities	2207.6.
3 Lia	abilities directly associated with assets in disposal group classified as held for sale	715
	gulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	3181.1"
	. Vial liabilities	
- -	Total equity and liabilities	4948.50

	Other Comprehensive Income			
	Date of start of reporting period	01-01-2025	01-04-2024	
	Date of end of reporting period	31-03-2025	31-03-2025	
	Whether results are audited or unaudited	Audited	Audited	
	Nature of report standalone or consolidated	Standalone	Standalone	
	Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss			
1	Remeasurement of net defined benefit liability - gain / (loss)	-15.94	-27.52	
	Total Amount of items that will not be reclassified to profit and loss	-15.94	-27.52	
2	Income tax relating to items that will not be reclassified to profit or loss	-4.15	-7.16	
3	Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss			
5	Total Other comprehensive income	-11.79	-20.36	

11	Particulars	Year ended (dd-mm-yyyy
9 1	Date of start of reporting period	01-04-20
	Date of end of reporting period	31-03-20
4	Whether results are audited or unaudited	Audit
	Nature of report standalone or consolidated	Standalo
Part I	Blue color marked fields are non-mandatory.	Standard
1	Statement of cash flows	
	Cash flows from used in operating activities	
11-	Profit before tax	-603.
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	188.
	Adjustments for decrease (increase) in inventories	-139.
	Adjustments for decrease (increase) in trade receivables, current	-73.
	Adjustments for decrease (increase) in trade receivables, non-current	
	Adjustments for decrease (increase) in other current assets	
	Adjustments for decrease (increase) in other non-current assets	4
	Adjustments for other financial assets, non-current	
	Adjustments for other financial assets, current	
	Adjustments for other bank balances	
	Adjustments for increase (decrease) in trade payables, current	-26
	Adjustments for increase (decrease) in trade payables, non-current	
	Adjustments for increase (decrease) in other current liabilities	-15
	Adjustments for increase (decrease) in other non-current liabilities	
	Adjustments for depreciation and amortisation expense	264
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	
	Adjustments for provisions, current	10
	Adjustments for provisions, non-current	
	Adjustments for other financial liabilities, current	
	Adjustments for other financial liabilities, non-current	
	Adjustments for unrealised foreign exchange losses gains	1
	Adjustments for dividend income	176
	Adjustments for interest income	4.
	Adjustments for share-based payments	
	Adjustments for fair value losses (gains)	
	Adjustments for undistributed profits of associates	
	Other adjustments for which cash effects are investing or financing cash flow	-3.
	Other adjustments to reconcile profit (loss)	71.
	Other adjustments for non-cash items	
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	
	Total adjustments for reconcile profit (loss)	102.82
	Net cash flows from (used in) operations	-500.81
	Dividends received	
	Interest paid	
1	Interest received	
	Income taxes paid (refund)	2.
	Other inflows (outflows) of cash	

3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	
	Cash flows used in obtaining control of subsidiaries or other businesses	
	Other cash receipts from sales of equity or debt instruments of other entities	
	Other cash payments to acquire equity or debt instruments of other entities	
	Other cash receipts from sales of interests in joint ventures	
	Other cash payments to acquire interests in joint ventures	
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	-
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	
	Proceeds from sales of property, plant and equipment	3.90
	Purchase of property, plant and equipment	142.
	Proceeds from sales of investment property	
	Purchase of investment property	-
	Proceeds from sales of intangible assets	
	Purchase of intangible assets	
	Proceeds from sales of intangible assets under development	
	Purchase of intangible assets under development	
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	
		0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	151.94
	Interest received	1.1
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-29.87
	Net cash flows from (used in) investing activities	-15.55
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	749.14
	Repayments of borrowings	48.46
	Payments of lease liabilities	48.46
	Dividends paid	
		0

0	Income taxes paid (refund)	2012.03
0	Other inflows (outflows) of cash	
512.01	Net cash flows from (used in) financing activities	
-7.22	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	
	Effect of exchange rate changes on cash and cash equivalents	5
-0	Effect of exchange rate changes on cash and cash equivalents	
-7.22	Net increase (decrease) in cash and cash equivalents	
7.26	Cash and cash equivalents cash flow statement at beginning of period	
0.04	Cash and cash equivalents cash flow statement at end of period	

							osure of Relat							Bo men	Additional	disclosure of re	lated pr	arty tran	sactions - appli	cable on	ly in case the	related party	transaction	relates
1 Op 2 Op 3 Op 4 Op 5 Op 6 Op 7 Op 8 Op 9 Op 10 Op 11 Op	entity /subs	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty				Value of the related		Value of	Date of Audit		are due party as	monies to either s a result	In case an incurred to		osed on obtedne	ly once,	Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	party transaction as approved by the audit committee	Remarks on approval by audit committee	party transaction ratified by	Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interes	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient or funds (endusage)	l I No
1	Ophthalmics Ltd.	AAACG7070R	The Lens Company		Step Down Subsidiary	Sale of goods or services		700	Approved			164.16	66	127.78					(amend	71.5			(endusage)	1
2	GKB Ophthalmics Ltd.	AAACG7070R	Lensco - The Lens Company	-	Step Down Subsidiary	Purchase of goods or services		700	Approved			0	0	0			1	-						+
3	GKB Ophthalmics Ltd.	AAACG7070R	GKB Vision Private Ltd.		Related Party	Purchase of goods or services		2500	Approved			13.53	123.12	0			1				1 1			+
4	GKB Ophthalmics Ltd.	AAACG7070R	GKB Vision Private Ltd.		Related Party	Sale of goods or services		2500	Approved			805.26	464.7	310.88			1	-	Triffic and					+
5	GKB Ophthalmics Ltd.	AAACG7070R	GKB Vision Private Ltd.		Related Party	Purchase of fixed assets		2500	Approved			39 04	236.86	82 61			+	-						-
6	GKB	AAACG7070R	GKB Vision Private Ltd.		Related Party	Any other transaction	Reimbursement of expenses	2500	Approved			0	0	0			-	-		-				+
7	GKB Ophthalmics Ltd.	AAACG7070R	GKB Vision FZC.		Associates/Entities under common	Sale of goods or services		500	Approved			0	0	0			-	-						_
8	GKB	AAACG7070R	GSV Ophthalmics Pvt. Ltd.		Subsidiary	Any other transaction	Lease Deposit	1000	Approved			1.72	35.98	37.7			+	+		_				_
9	GKB Ophthalmics Ltd.	AAACG7070R	GSV Ophthalmics Pvt. Ltd.		Subsidiary	Any other transaction	Lease rent income	1000	Approved			0	0	0			-	-						_
10	GKB Ophthalmics	AAACG7070R	GSV Ophthalmics		Subsidiary	Any other transaction	Reimbursement	1000	Approved			0	0	0			-	+						_
	Ltd.		Pvt. Ltd.			transaction	of expenses		-		-						_	4			One year			
11	GKB Ophthalmics Ltd.	AAACG7070R	GSV Ophthalmics Pvt. Led	and the second	Subsidiary	Any other transaction	Loan availed from Subsidiary Company	500	Approved			500	0	500					Loan i	0.65%	moratorium from the end of the month in which the fund is received by the borrower, followed by		For the working capital requirement and general business purpose.	

	1	1	1	3		1 1	1		1 1		1				-	1	-			+
13	GKB Ophthalmics Ltd.	AAACG7070R	KG Gupta		Managing Director	Remuneration		65	Approved			24.9	0	0						Ī
14	GKB Ophthalmics	AAACG7070R	Cedric Lobo	_	Executive Director	Remuneration		12	Approved			5.19	0	0						
15		AAACG7070R	Vikram Gupta		Non-Executive Director	Any other transaction	Director's Sitting Fees	2	Approved			0.1	0	0						
16		AAACG7070R	Purushottam Mantri		Independent Director	Any other transaction	Director's Sitting Fees	2	Approved			0.8	0	0						Ī
17	GKB Ophthalmics	AAACG7070R	Shashi Katreddi		Independent Director	Any other transaction	Director's Sitting Fees	2	Approved	177,14		1	0	0					000	Ī
18	GKB Ophthalmics	AAACG7070R	Ninad Kamat		Independent Director	Any other transaction	Director's Sitting Fees	2	Approved			0.8	0	0						Ī
19	GKB Ophthalmics	AAACG7070R	Sandhya Kamat		Independent Director	Any other transaction	Director's Sitting Fees	2	Approved			0.5	0	0		-		n bootes	1/ 1 1 14	1
20	GKB Ophthalmics	AAACG7070R	Gurudas Sawant		Key Managerial Personnel	Remuneration		18	Approved			6.48	0	0		Male I				İ
21	GKB Ophthalmics	AAACG7070R	Pooja Bicholkar		Key Managerial Personnel	Remuneration		12	Approved			4.87	0	0		Proget I				T
22		AAACG7070R			Managing Director	Any other transaction	Loan availed from Managing	3	Approved			300	0	296		Sere3				1
23	GKB Ophthalmics Products	7272299992	GKB Vision Private Ltd.		Related Party	Purchase of goods or services	Director	1500	Approved			217.93	345.64	304.79		Garage Con-				1
24	GKB Ophthalmics Products	ZZZZZ9999Z	GKB Vision Private Ltd.		Related Party	Sale of goods or services		1500	Approved			63.06	161.9	61.78						Ī
25	GKB Ophthalmics Products	2222299992	GKB Vision Private Ltd.	AABCG2608N	Related Party	Any other transaction	Reimbursement of expenses	1500	Approved			2.68	0	0		-				Ī
26	GKB Ophthalmics Products	77.77.7.99997.	Lensco - The Lens	7222299997.	Subsidiary Company	Sale of goods or services		800	Approved			42.54	210.56	176.72		V-T-T-				Ī
27	GKB Ophthalmics Products	27.727.99997.	Lensco - The Lens Company	7222299992	Subsidiary Company	Purchase of goods or services		800	Approved			8.16	0	8.24		LETTER				
28	GKB Ophthalmics Products	ZZZZZ9999Z	GKB Vision FZC	ZZZZZ9999Z	Associate Company	Purchase of goods or services		2200	Approved			474.42	962.78	602.81						1
29	GKB Ophthalmics Products	7777799997	GKB Vision FZC	ZZZZ29999Z	Associate Company	Sale of goods or services		2200	Approved			139.78	122.47	109.04						
30	GKB Ophthalmics Products FZE	ZZZZ29999Z	GKB Vision FZC	7777799997	Associate Company	Any other transaction	Reimbursement of expenses	2200	Approved			8.39	8.57	2.38		1004==1				
31	GKB Ophthalmics Products FZE	ZZZZZ9999Z	Prescription Optical Products LLC	7.7.7.7.99997	Subsidairy Company	Sale of goods or services		800	Approved			285.7	57.73	72.86						
32	GKB Ophthalmics Products FZE	7.7.7.7.7.99997	Prescription	7.7.7.7.7.99997	Subsidairy Company	Any other transaction	Reimbursement of expenses	800	Approved			5,26	0	0		F-12-12-12-12-12-12-12-12-12-12-12-12-12-				

33	Ophthalmics Products FZE	ZZZZZ9999Z	Ophthalmics Procts PTY Ltd.	ZZZZZ9999Z	Step Down Subsidiary	Sale of goods or services		260	Approved		0.46	0	0.46	
34	GKB Ophthalmics Products FZE	ZZZZ29999Z	Prime Ophthalmics Procts PTY Ltd.	ZZZZZ9999Z	Step Down Subsidiary	Any other transaction	Reimbursement of expenses	260	Approved		32.1	0	0	
35	Lensco - The Lens Company	7222299992	GKB Vision Private Ltd	AABCG2608N	Related Party	Sale of goods or services		1100	Approved		1.83	3.87	1.85	
36	Lensco - The Lens Company	7222299992	GKB Vision Private Ltd	AABCG2608N	Related Party	Purchase of goods or services		1100	Approved		518.8	496.16	867.69	
37	Lensco - The Lens Company	7222299992	GKB Vision FZC	ZZZZZ9999Z	Related Party	Sale of goods or services		200	Approved		0	0	0	
38	Lensco - The Lens Company	ZZZZ29999Z	GKB Vision FZC	ZZZZZ9999Z	Related Party	Purchase of fixed assets		200	Approved		0	0	0	
39	Lensco - The Lens Company	ZZZZ29999Z	Shefali Chawla	ABMPC9140Q	Related Party	Any other transaction	Loan availed from Mrs. Shefali Chawla	253	Approved		141.01	0	141.01	
40	Lensco - The Lens Company	ZZZZZ9999Z	Gaurav Gupta	AECPK7502D	Related Party	Remuneration		63.74	Approved		32.34	0	0	
Total value of transaction during the reporting period						,			,	,	3845.21			

	Details of Impact of Audit Qualific	cation	
Whether results are	e audited or unaudited	Audited	Jie alv. I
Declaration of unn	nodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursua declares that its Sta period on Standalo	nt to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company attutory Auditor/s have issued an Audit Report with unmodified opinion for the ne results	Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	MSKA & Associates	Yes	31-07-2027

	1 or mar for Discrosing Outs	muning D	efault on Loans and Debt Securities
Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / finance	ial instituti	ons
A	Total amount outstanding as on date	944.68	
В	Of the total amount outstanding, amount of default as on date	3.75	This interest of Rs. 3,75,397 /- was Outstanding as on March 31,2025 and duly covered by bank on April 03, 2025.
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
В	Of the total amount outstanding, amount of default as on date	0	21901.2.11.12.2.12
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	1741.14	

General information about company	
Scrip code*	533212
NSE Symbol*	NOTLISTED
MSEI Symbol*	BSE
ISIN*	INE265D01015
Name of company	GKB Ophthalmics Limited
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	30-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	14-05-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	OPHTHALMIC LENSES
Start date and time of board meeting	30-05-2025 17:15
End date and time of board meeting	30-05-2025 18:06
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

_		Financia	l Results – Ind-AS			
		Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures fo period ended (dd-mr	current -yyyy)	1960
	_	Date of start of reporting period	01-01-2025	(	1-04-2024	
		Date of end of reporting period	31-03-2025		1-03-2025	
		Whether results are audited or unaudited	Audited		Audited	
		Nature of report standalone or consolidated	Consolidated	Co	nsolidated	
Par	t Blue	color marked fields are non-mandatory. For Consolidated zero shall be inserted in the said column.	Results, if the company has r			ded, in suc
1	Inco					1
	Reve	enue from operations	212221		-	415-2-2
		r income	3102.29		10898.76	
		Totalinama	33.62		133.1	
2	Expe	Total income	3135.91		11031.86	
(a)	1					
(b)	1	Cost of materials consumed	646.17		2115.32	
	Chi	Purchases of stock-in-trade anges in inventories of finished goods, work-in-progress and	1868.01		6175.65	
(c)		stock-in-trade	-263.11		-946.37	
(d)		Employee benefit expense	453.84		1725.74	
(e)		Finance costs	63.04		237.08	
(f)		Depreciation, depletion and amortisation expense	79.92		308.7	
(g)	Other	Expenses				
1	Other	Expenses	682.69		2106.67	
		Total other expenses	682.69	History - Design	2106.67	
		Total expenses	3530.56		11722.79	
3		Total profit before exceptional items and tax	-394.65		-690.93	
4	Excep	tional items	0		0	
5		Total profit before tax	-394.65		-690.93	
6	Tax es	xpense			-050.55	
7	Curren	nt tax	15.28		28.14	
8	Deferm	ed tax	4.15		7.16	
9		Total tax expenses	19.43			
10	Net n	novement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0		35.3	
11	Ne	et Profit Loss for the period from continuing operations	-414.08		-726.23	
12		Profit (loss) from discontinued operations before tax	0		0	
13		Tax expense of discontinued operations	0		0	
14		Net profit (loss) from discontinued operation after tax	0		0	
15	Shan	e of profit (loss) of associates and joint ventures accounted for using equity method	1.2		18.31	
16		Total profit (loss) for period	-412.88		-707.92	
17		Other comprehensive income net of taxes	-11.79		-20.36	
18		Total Comprehensive Income for the period	-424.67		-728.28	
19	Total p	rofit or loss, attributable to				
	Profit o	r loss, attributable to owners of parent	-354.59		-704.48	
	Total pr	rofit or loss, attributable to non-controlling interests	-58.29		-3.44	
0		comprehensive income for the period attributable to	20.27		-3.44	
		thensive income for the period attributable to owners of	-366.38	-	-724.84	
1	Total co	imprehensive income for the period attributable to owners	-58.29		2.44	
	OF DRUCH	it non-controlling interests	-38.29		-3.44	

21	Details of equity share capital							
	Paid-up equity share capital	504.06	504.06					
	Face value of equity share capital	10	10					
22	Reserves excluding revaluation reserve		4699.83					
23	Earnings per share							
i	Earnings per equity share for continuing operations							
	Basic earnings (loss) per share from continuing operations	-7.03	-13.98					
	Diluted earnings (loss) per share from continuing operations	-7.03	-13.98					
ii	Earnings per equity share for discontinued operations							
	Basic earnings (loss) per share from discontinued operations	0	0					
1	Diluted earnings (loss) per share from discontinued operations	0	0					
iii	Earnings per equity share (for continuing and discontinued operations)							
	Basic earnings (loss) per share from continuing and discontinued operations	-7.03	-13.98					
	Diluted earnings (loss) per share from continuing and discontinued operations	-7.03	-13.98					
24	Debt equity ratio	· ·		Textual Information(1)				
25	Debt service coverage ratio			Textual Information( 2)				
26	Interest service coverage ratio			Textual Information( 3)				
27	Disclosure of notes on financial results	Textual Information(4)						

## Text Block

- 3. The consolidated financial results include results of the following companies:
- Name of the Company Relationship
- 1. GKB Ophthalmics Limited Holding Company
- 2. GSV Ophthalmics Private Limited Subsidiary
- 3.GKB Ophthalmics Products [FZE] Wholly Owned Subsidiary

(including its following Subsidiaries and Associate)

- a. Lensco The lens company (Subsidiary)
- b. Prescription Optical Products LLC (Subsidiary)
- c. PRIME OPHTHALMIC PRODUCTS (PTY) LTD (Subsidiary)
- d. GKB Vision FZC (Associate 49% Holdin
- 4.1 heaboveconsolidated in an ciaire suits in a voice medical committee and approved by the Board of Directors of the Holding Comman vattheir respective meetings held on May 30, 2025. The consolidated annual financial results have been subject to audit by the State of the Holding Comman vattheir respective meetings held on May 30, 2025. The consolidated annual financial results have been subject to audit by the State of the Holding Comman vattheir respective meetings held on May 30, 2025. The consolidated annual financial results have been subject to audit by the State of the Holding Comman vattheir respective meetings held on May 30, 2025. The consolidated annual financial results have been subject to a subjec

## Textual Information

- 5. The utilisation / status of funds raised from preferential issue is as follows:-
- Particulars As at March 31, 2025 As at March 31, 2024

(Rs. In lakhs) (Rs. In lakhs)

Towards funding growth plans - organic and inorganic 1170.00 1170.00

Towards scaling up of operations, long term capital

requirements and other general corporate purpose 335.05 335.05

Total funds utilised (A) 1505.05 1505.05

Unutilised amount lying in Escrow account (B) - 7.22

Total funds raised (A + B) 1512.27 1512.27

- 6.The Group operates in one primary segment only, i.e. Ophthalmics Lenses and therefore Ind AS 108 -Operating Segment is not applicable.
- 7. The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the statutory auditors.
- 8. The figures of the previous year / periods have been reclassified / regrouped wherever necessary to confirm to current year.

	Particulars	Year ended (dd-mm-y	1220
	Date of start of reporting perio		ууу)
	Date of end of reporting period		
	Whether results are audited or unaudited  Nature of report standalone or consolidated		
1	Assets	Consolidated	
	Non-current assets		
	Property, plant and equipment	1	
	Capital work-in-progress		1703.
	Investment property	-	390.
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	1	
	Non-current investments	pita - pa	201.2
4	Trade receivables, non-current		
1	.coans, non-current		= 45
	Other non-current financial assets	7 1 0 790	4
	Total non-current financial assets	A-1	206.1
1	Deferred tax assets (net)		10.9
(	Other non-current assets		271
	Total non-current assets		2582.4
2 (	Current assets		
1	nventories	5	5037.7
(	Current financial asset		
0	Current investments	1 6	0.0
T	rade receivables, current	2	2549.1
0	Cash and cash equivalents		302.1
В	eank balance other than cash and cash equivalents		080.0
	oans, current	-	1000.0
0	other current financial assets		
1	Total current financial assets	-	49.1
10	urrent tax assets (net)	3	980.5
	ther current assets		
	otal current assets		920.6
N	on-current assets classified as held for sale		9939
-,-	egulatory deferral account debit balances and related deferred tax Assets		
1	otal assets		
1			521.47
N	Total current assets on-current assets classified as held for sale	9939	
	egulatory deferral account debit balances and related deferred tax Assets		
1			
E	Total assets	12521.47	
	quity and liabilities		
	quity		
	quity attributable to owners of parent		
	uity share capital	5	504.06
Ot	her equity	46	599.83
	Total aguity attributable to account	5202.00	
-	Total equity attributable to owners of parent	5203.89	

Non controlling interest	439.76
Total equity	5643.65
2 Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	308.16
Trade Payables, non-current	
(A) Total outstanding dues of micro enterprises and small enterprises	
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	\$100 (100 m)
Total Trade payable	0
Other non-current financial liabilities	
Total non-current financial liabilities	308.16
Provisions, non-current	331.04
Deferred tax liabilities (net)	
Deferred government grants, Non-current	
Other non-current liabilities	
Total non-current liabilities	639.2
Current liabilities	an afternoon to a
Current financial liabilities	
Borrowings, current	1141.4
Trade Payables, current	
(A) Total outstanding dues of micro enterprises and small enterprises	122.7
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3805.8
Total Trade payable	3928.55
Other current financial liabilities	212.8
Total current financial liabilities	5282.86
Other current liabilities	867.5
Provisions, current	88.2
Current tax liabilities (Net)	
Deferred government grants, Current	
Total current liabilities	6238.62
Liabilities directly associated with assets in disposal group classified as held for sale	
Regulatory deferral account credit balances and related deferred tax liability	
Total liabilities	6877.82
Total equity and liabilities	12521.47
Disclosure of notes on assets and liabilities	Textual Information(1)

_	Other Comprehensive Income		
_	Date of start of reporting period	01-01-2025	01-04-2024
_	Date of end of reporting period	31-03-2025	31-03-2025
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]		-
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurement of net defined benefit liability	-15.94	-27.52
	Total Amount of items that will not be reclassified to profit and loss	-15.94	-27.52
2	Income tax relating to items that will not be reclassified to profit or loss	-4.15	-7.16
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	-11.79	-20.36

	Particulars	Year ended (dd-mm-yyyy)
9 10	Date of start of reporting period	01-04-202
9 12	Date of end of reporting period	31-03-202
1111	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory.	- Consortance
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-690.93
2	Adjustments for reconcile profit (loss)	-090.93
	Adjustments for finance costs	237.08
	Adjustments for decrease (increase) in inventories	-1035.9
	Adjustments for decrease (increase) in trade receivables, current	-258.21
	Adjustments for decrease (increase) in trade receivables, non-current	- 238.21
	Adjustments for decrease (increase) in other current assets	
	Adjustments for decrease (increase) in other non-current assets	-814.32
	Adjustments for other financial assets, non-current	19.27
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	-15.37
	Adjustments for increase (decrease) in trade payables, current	0
	Adjustments for increase (decrease) in trade payables, non-current	597.63
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	811.03
	Adjustments for depreciation and amortisation expense	0
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	308.7
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	522.74
	Adjustments for other financial liabilities, current	0
		66.55
_	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains  Adjustments for dividend income	-1.67
		0.04
	Adjustments for interest income	107.43
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-3.98
	Other adjustments to reconcile profit (loss)	36.68
	Other adjustments for non-cash items	-1.25
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	3-1.51
	Net cash flows from (used in) operations	29.42
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	13.55
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	342.97
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0

	Other cash receipts from sales of equity or debt instruments of other entities	
	Other cash payments to acquire equity or debt instruments of other entities	
	Other cash receipts from sales of interests in joint ventures	
	Other cash payments to acquire interests in joint ventures	
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	
	Proceeds from sales of property, plant and equipment	3.9
	Purchase of property, plant and equipment	214.7
	Proceeds from sales of investment property	214.7
	Purchase of investment property	
	Proceeds from sales of intangible assets	
	Purchase of intangible assets	
	Proceeds from sales of intangible assets under development	
	Purchase of intangible assets under development	
	Proceeds from sales of goodwill	
	Purchase of goodwill	
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0.04
	Interest received	89.48
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	376.19
	Net cash flows from (used in) investing activities	254.97
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	
	Repayments of borrowings	390.15
		89.24
	Payments of lease liabilities	224.02
	Payments of lease liabilities  Dividends paid	234.03
	Dividends paid	0
	Dividends paid  Interest paid	0
	Dividends paid  Interest paid  Income taxes paid (refund)	0 0
	Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash	0 0 0
	Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities	0 0
	Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0 0 0
s	Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes  Effect of exchange rate changes on cash and cash equivalents	0 0 0 0 66.88
5	Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0 0 0 0 66.88

Cash and cash equivalents cash flow statement at beginning of period	323.24
Cash and cash equivalents cash flow statement at end of period	302.12

	Details of Impact of Audit Qualific	cation	
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	MSKA & Associates	Yes	31-07-2027